Welcome to our dedicated page for Picard Medical SEC filings (Ticker: PMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This Picard Medical, Inc. (PMI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Picard Medical is a Delaware corporation listed on the NYSE American, and its filings describe a business conducted through SynCardia Systems, LLC, a medical technology company that manufactures and sells the SynCardia Total Artificial Heart (STAH) for patients with advanced heart failure.
Through documents such as Form S-1 registration statements and Form 8-K current reports, investors can review detailed information about Picard Medical’s operations, financing arrangements, and risk factors. The S-1 filing explains that SynCardia’s platform includes the SynCardia 50cc and 70cc total artificial hearts, external drivers, ancillary hardware, and associated surgeon and center training. It also notes that the company’s customers are major medical centers operating heart transplant and mechanical circulatory support programs and that SynCardia operates an ISO 13485–certified quality management system.
Form 8-K filings for Picard Medical include disclosures on material definitive agreements, such as senior secured notes and warrant financings, bridge financing arrangements, and related security agreements. Additional 8-Ks furnish press releases and presentation materials related to clinical and technical updates on the next-generation, fully implantable Emperor Total Artificial Heart, as well as corporate events like conference presentations and exchange bell-ringing ceremonies.
On this page, users can follow real-time updates from EDGAR and use AI-powered summaries to understand the key points in lengthy filings. Forms such as the S-1, 8-K, and any future 10-K annual reports, 10-Q quarterly reports, or proxy statements can provide insight into Picard Medical’s capital structure, governance, risk profile, and the progress of its SynCardia and Emperor total artificial heart platforms. Insider transaction reports on Form 4, when available, can also be reviewed to see changes in beneficial ownership by company insiders.
Picard Medical, Inc. used a pre-recorded presentation for its 2026 Annual Meeting to update stockholders on business performance, product development, and voting proposals. Management reported first-quarter revenue growth of 85% year over year and a 28% improvement in gross margin, with U.S. revenue up 116% and representing most product revenue. The company is advancing its next-generation Emperor Total Artificial Heart platform, aiming to eliminate external pneumatic drivers and support internal power, wireless control, and transcutaneous energy transfer, supported by several issued patents. The development roadmap targets an FDA Breakthrough Device submission in 2026, GLP animal studies in 2027, IDE submission in 2028, and an early feasibility U.S. clinical study in 2029. Picard detailed a capital structure with slightly more than 92 million shares outstanding and a fully diluted share count of slightly more than 118 million. Stockholders are asked to vote on six proposals, including director elections, a reverse stock split in a range of 1-for-15 to 1-for-50 to help address New York Stock Exchange listing requirements, creation of a high-vote Class B common stock with 20 votes per share, auditor ratification, and advisory votes on executive compensation and its frequency.
Picard Medical, Inc. furnished a press release and a pre-recorded presentation dated July 2, 2026 announcing the availability of a presentation in advance of its 2026 Annual Meeting of Stockholders, scheduled for July 17, 2026. The company filed the press release and presentation as Exhibit 99.1 and Exhibit 99.2 to this report.
Picard Medical, Inc. filed a current report describing a pre-recorded presentation released ahead of its 2026 virtual Annual Meeting on July 17, 2026. The presentation highlights recent business performance, including an 85% year-over-year increase in revenue and an improved gross margin of 28% from year-end 2025, driven by a 116% increase in U.S. revenue.
The company outlines manufacturing optimization initiatives and progress on its next-generation Emperor total artificial heart platform, which replaces the external pneumatic driver with an electromechanical system and has a roadmap toward a fully implantable device. Development plans include pursuit of FDA Breakthrough Device designation, an Investigational Device Exemption submission in 2028, and planned clinical study activities in 2029. The presentation also reviews proposals for director elections, capital structure changes, auditor ratification, and advisory votes on executive compensation to be considered at the Annual Meeting.
Picard Medical, Inc. reported that on June 23, 2026, Dr. Joe Xiao was appointed to its Board of Directors, with his term set to expire at the Company’s 2026 annual meeting of stockholders. He will serve on the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, giving him a broad governance role across financial oversight, executive pay and board nominations.
Dr. Xiao entered into Picard Medical’s standard indemnification agreement for directors and will be paid under the existing compensation policy for non-employee directors described in the proxy statement filed on June 15, 2026. The Company states there are no special arrangements behind his selection and no related-party transactions requiring disclosure, indicating this is a routine independent board appointment.
Picard Medical, Inc. is asking stockholders to vote at an online annual meeting on July 17, 2026. Holders of 102,695,935 common shares as of June 26, 2026 may vote.
Key items include electing four directors, advisory votes on executive pay and how often that vote should occur, and ratifying MaloneBailey LLP as auditor for 2026. The Board also seeks authority to implement a reverse stock split between 1‑for‑15 and 1‑for‑50, with a proportional cut to authorized shares, to help address NYSE American listing standards.
Another proposal would create a new Class B common stock with 15,000,000 authorized shares, each carrying 20 votes, which could concentrate voting power if issued. The proxy notes NYSE American notices citing stockholders’ equity of about $3.8 million at December 31, 2025 and a stockholders’ deficit of about $(1.4) million at March 31, 2026, and references a compliance plan running through November 8, 2027.
Picard Medical, Inc. announced a planned leadership transition, with Patrick NJ Schnegelsberg stepping down as Chief Executive Officer and board member effective June 18, 2026. The company states his departure is not due to any disagreement over operations, policies, or practices.
The Board appointed Chairman Richard Fang, Ph.D., age 60, as Interim Chief Executive Officer effective the same date, while it searches for a permanent CEO. He will continue as Chairman and receive an annual salary of $400,000 in the interim role.
Fang previously served as CEO from September 2021 to July 2023 and has extensive med-tech and venture capital experience, including founding Reach Surgical and leading it over a 15-year period. Picard’s SynCardia unit manufactures the only FDA- and Health Canada–approved total artificial heart, with more than 2,100 implants across 27 countries.
Picard Medical, Inc. is asking shareholders to vote at its virtual Annual Meeting on July 17, 2026 (record date: June 26, 2026). Key matters include election of four directors, advisory votes on executive pay, and two Charter amendments: a board-authorized reverse stock split at a ratio of 1-for-15 to 1-for-50 and designation of 15,000,000 shares of Class B common stock with 20 votes per share. The proxy explains the board’s rationale for the reverse split, citing NYSE American non-compliance notices based on stockholders’ equity of approximately $3.8M as of December 31, 2025 and a reported stockholders’ deficit of $(1.4)M as of March 31, 2026. The company submitted a compliance plan to regain listing compliance by November 8, 2027. Other routine items include ratification of MaloneBailey LLP as auditor and amendments to the charter to implement approved changes.
Picard Medical, Inc. filing amends a previously submitted Schedule 13G to report that the listed Reporting Persons beneficially own 0 shares of Common Stock, $0.0001 par value (CUSIP 740459102). The amendment is signed by an attorney-in-fact and dated 06/05/2026.
PMI filed Form 144 notices reporting proposed sales of Common Stock. The filing lists an entry of 3,971,793 shares tied to a debt exchange for equity dated 09/01/2021 and shows transactions by Sindex SSI Lending, LLC of 628,082 shares on 06/01/2026 and 3,343,711 shares on 06/02/2026. The document records the recipient broker as Wells Fargo Clearing Services and identifies the market as NYSE.
Picard Medical, Inc. reported a leadership change in its finance organization effective June 1, 2026. Bernard Skaggs was terminated as Chief Financial Officer, effective immediately. The Board appointed Georgina Smith, 54, as Chief Accounting Officer on the same date, adding senior oversight to the Company’s accounting and reporting functions.
Smith previously served as Controller of SynCardia Systems, LLC, a Picard Medical subsidiary, from January 2026 to May 2026, and earlier held senior accounting roles at Rain Bird Corporation and Tucson Electric Power. She holds both MBA and accounting degrees from the University of Arizona and is a Certified Public Accountant in Arizona. The Company states there are no special arrangements tied to her selection and no related party transactions requiring disclosure.